Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition from being a subsidiary of Fosun Pharmaceutical to a joint venture.

CEC Capital Group acted as the exclusive financial advisor for Fosun Pharmaceutical in this transaction.

YanengBIO is a leading domestic enterprise engaged in the research, development, production, and sales of molecular diagnostic reagents and instruments. With over 20 years of experience in the molecular diagnostics field, the company focuses on HPV (Human Papillomavirus) cervical cancer screening, thalassemia gene testing for Mediterranean anemia, and other molecular diagnostic reagent products in the field of maternal and child health. Other molecular diagnostic reagent products include Y chromosome microdeletion gene testing, tuberculosis mycobacterium gene testing, and deafness gene testing. The company holds a prominent position in the fields of HPV testing and Mediterranean anemia gene testing, maintaining a leading market share domestically for multiple consecutive years. It has obtained over 50 medical device registration certificates issued by the National Medical Products Administration and possesses a rich pipeline of ongoing research and development projects.